Language impairment in alzheimer's disease and benefits of acetylcholinesterase inhibitors

Clinical Interventions in Aging

Volumn 8, Issue , 2013, Pages 1007-1014

  Ferris, Steven H ^a   Farlow, Martin ^b  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Clinical trials; Cognition; Communication; Donepezil; Language

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; PLACEBO; RIVASTIGMINE; CARBAMIC ACID DERIVATIVE; INDAN DERIVATIVE; PIPERIDINE DERIVATIVE;

ALZHEIMER DISEASE; CAREGIVER BURDEN; CLINICAL FEATURE; COGNITION; DEPTH PERCEPTION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG MEGADOSE; ECHOLALIA; ENZYME INHIBITION; FUNCTIONAL STATUS; HUMAN; INTERPERSONAL COMMUNICATION; LANGUAGE DISABILITY; LANGUAGE PROCESSING; LOW DRUG DOSE; MEMORY; NEUROLOGIC EXAMINATION; PATIENT MONITORING; QUALITY OF LIFE; REVIEW; SCORING SYSTEM; SEMANTICS; SOCIAL BEHAVIOR; SOCIAL PSYCHOLOGY; STEREOTYPY; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; COMMUNICATION DISORDERS; COMPLICATION; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COMMUNICATION DISORDERS; GALANTAMINE; HUMANS; INDANS; OUTCOME ASSESSMENT (HEALTH CARE); PHENYLCARBAMATES; PIPERIDINES;

EID: 84881062258     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/CIA.S39959     Document Type: Review

References (40)

1. Alzheimer's Disease International. World Alzheimer Report 2010: The global economic impact of dementia. Alzheimer's Disease Inter-national website. Available from: http://www.alz.co.uk/research/files/WorldAlzheimerReport2010.pdf. Accessed May 10, 2012.
2. Alzheimer's Association. 2012 Alzheimer's Disease Facts and Figures. Alzheimer's and Dementia. Available from: http://www.alz.org/downloads/Facts_Figures_2012.pdf. Accessed May 10, 2012.
3. Hebert LE, Scherr PA, Bienias JL, Bennett D., Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003;60(8):1119-1122.
4. Feldman HH, Woodward M. The staging and assessment of moderate to severe Alzheimer disease. Neurology. 2005;65:S10-S17.
5. Gelb DJ. Measurement of progression in Alzheimer's disease: a clini-cian's perspective. Stat Med. 2000;19(11-12):1393-1400.
6. Vestal L, Smith-Olinde L, Hicks G, Hutton T, Hart J Jr. Efficacy of lan-guage assessment in Alzheimer's disease: comparing in-person exami-nation and telemedicine. Clin Interv Aging. 2006;1(4):467-471.
7. Schwam E, Xu Y. Cognition and function in Alzheimer's disease: iden-tifying the transitions from moderate to severe disease. Dement Geriatr Cogn Disord. 2010;29(4):309-316.
8. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of demen-tia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3): 263-269.
9. Mesulam M, Wicklund A, Johnson N, et al. Alzheimer and frontotem-poral pathology in subsets of primary progressive aphasia. Ann Neurol. 2008;63(6):709-719.
10. Rohrer JD, Rossor MN, Warren JD. Alzheimer's pathology in primary progressive aphasia. Neurobiol Aging. 2012;33(4):744-752.
11. Savundranayagam MY, Hummert ML, Montgomery RJ. Investigating the effects of communication problems on caregiver burden. J Gerontol B Psychol Sci Soc Sci. 2005;60(1):S48-S55.
12. Ripich DN. Functional communication with AD patients: a caregiver training program. Alzheimer Dis Assoc Disord. 1994;8 Suppl 3: 95-109.
13. Manenti R, Repetto C, Bentrovato S, Marcone A, Bates E, Cappa SF. The effects of ageing and Alzheimer's disease on semantic and gender priming. Brain. 2004;127(Pt 10):2299-2306.
14. Tang-Wai DF, Graham NL. Assessment of language function in dementia. Geriatr Aging. 2008;11:103-110.
15. Arrighi HM, Neumann PJ, Lieberburg IM, Townsend RJ. Lethality of Alzheimer disease and its impact on nursing home placement. Alzheimer Dis Assoc Disord. 2010;24(1):90-95.
16. Galasko D, Schmitt F, Thomas R, Jin S, Bennett D. Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease. J Int Neuropsychol Soc. 2005;11(4):446-453.
17. Hilari K, Needle JJ, Harrison KL. What are the important factors in health-related quality of life for people with aphasia? A systematic review. Arch Phys Med Rehabil. 2012;93(Suppl 1):S86-S95.
18. Lam JM, Wodchis WP. The relationship of 60 disease diagnoses and 15 conditions to preference-based health-related quality of life in Ontario hospital-based long-term care residents. Med Care. 2010;48(4): 380-387.
19. Bracco L, Gallato R, Grigoletto F, et al. Factors affecting course and survival in Alzheimer's disease. A 9-year longitudinal study. Arch Neurol. 1994;51(12):1213-1219.
20. Cosentino S, Scarmeas N, Albert SM, Stern Y. Verbal fluency predicts mortality in Alzheimer disease. Cogn Behav Neurol. 2006;19(3): 123-129.
21. Potkins D, Myint P, Bannister C, et al. Language impairment in dementia: impact on symptoms and care needs in residential homes. Int J Geriatr Psychiatry. 2003;18(11):1002-1006.
22. Northcott S, Hilari K. Why do people lose their friends after a stroke? Int J Lang Commun Disord. 2011;46(5):524-534.
23. Robert P, Ferris S, Gauthier S, Ihl R, Winblad B, Tennigkeit F. Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice? Alzheimers Res Ther. 2010;2(4):24.
24. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141(11):1356-1364.
25. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001;57(3):489-495.
26. Schmitt FA, Cragar D, Ashford JW, et al. Measuring cognition in advanced Alzheimer's disease for clinical trials. J Neural Transm Suppl. 2002;62:135-148.
27. Emre M, Mecocci P, Stender K. Pooled analyses on cognitive effects of memantine in patients with moderate to severe Alzheimer's disease. J Alzheimers Dis. 2008;14(2):193-199.
28. Schmitt FA, Ashford W, Ernesto C, et al. The severe impairment bat-tery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11 Suppl 2:S51-S56.
29. Ferris S, Ihl R, Robert P, et al. Severe Impairment Battery Language scale: a language-assessment tool for Alzheimer's disease patients. Alzheimers Dement. 2009;5(5):375-379.
30. Schultz RR, Siviero MO, Bertolucci PHF. The cognitive subscale of the "Alzheimer's Disease Assessment Scale" in a Brazilian sample. Braz J Med Biol Res. 2001;34:1295-1302.
31. Ferris SH, Schmitt FA, Saxton J, et al. Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease. Alzheimers Res Ther. 2011;3(3):22.
32. Winblad B, Kilander L, Eriksson S, et al. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet. 2006;367(9516):1057-1065.
33. Black SE, Doody R, Li H, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology. 2007;69(5):459-469.
34. Cummings J, Jones R, Wilkinson D, et al. Effect of donepezil on cogni-tion in severe Alzheimer's disease: a pooled data analysis. J Alzheimers Dis. 2010;21(3):843-851.
35. Winblad B, Black SE, Homma A, et al. Donepezil treatment in severe Alzheimer's disease: a pooled analysis of three clinical trials. Curr Med Res Opin. 2009;25(11):2577-2587.
36. Farlow MR, Salloway S, Tariot PN, et al. Effectiveness and tolerabil-ity of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: a 24-week, randomized, double-blind study. Clin Ther. 2010;32(7):1234-1251.
37. Schmitt FA, Ferris SH, Mackell J, Richardson S, Sun Y. Donepezil 23 mg/d improves cognitive abilities in patients with moderate to severe Alzheimer's disease: evaluating the impact on language. Presented at the 63rd Annual Meeting of the American Academy of Neurology, Honolulu, HI, April 9-16, 2011.
38. Burns A, Bernabei R, Bullock R, et al. Safety and efficacy of galan-tamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial. Lancet Neurol. 2009;8(1):39-47.
39. Farlow MR, Cummings JL, Olin J., Meng X. Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2010;25(4):347-352.
40. Grossberg GT, Schmitt FA, Meng X, Tekin S, Olin J. Reviews: effects of transdermal rivastigmine on ADAS-cog items in mild-to-moderate Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2010;25(8):627-633.